Financial Performance - The company reported a revenue of RMB 11,334,262,000 for 2022, an increase of 16.8% compared to 2021[2]. - Profit attributable to shareholders was RMB 1,581,094,000, reflecting a growth of 60.0% year-on-year[2]. - Basic earnings per share increased to RMB 86.89, up 61.8% from RMB 53.70 in the previous year[2]. - The total revenue for the year ended December 31, 2022, was RMB 11,334,262, an increase of 16.7% compared to RMB 9,703,438 in 2021[11]. - Gross profit for the year was RMB 4,968,990, representing a gross margin of approximately 43.8%, up from RMB 4,211,047 in the previous year[11]. - The net profit for the year was RMB 1,581,023, which is a 59.8% increase from RMB 989,585 in 2021[11]. - Total comprehensive income for the year amounted to RMB 1,582,450, up from RMB 990,060 in 2021, indicating strong overall performance[12]. - The group reported a total revenue of RMB 11,334,262 thousand for the year ending December 31, 2022, compared to RMB 9,703,438 thousand for the previous year, representing an increase of approximately 16.7%[23][25]. - The group’s pre-tax profit for the year ending December 31, 2022, was RMB 1,202,647 thousand, a decrease from RMB 2,006,766 thousand in 2021[22][23]. - The group’s bank interest income increased to RMB 70,737 thousand in 2022 from RMB 51,594 thousand in 2021, reflecting a growth of approximately 37%[26]. - The group reported a net loss from other income and expenses of RMB 88,571 thousand in 2022, compared to a net loss of RMB 19,256 thousand in 2021[27]. - The group’s total other income for 2022 was RMB 165,817 thousand, slightly up from RMB 155,879 thousand in 2021, showing a growth of about 6.2%[26]. - Interest expenses increased to RMB 87,971,000 in 2022 from RMB 63,532,000 in 2021, reflecting a growth of 38.5%[28]. - Corporate income tax expenses rose significantly to RMB 401,231,000 in 2022, compared to RMB 164,864,000 in 2021, marking an increase of 143.5%[29]. - The total tax expenses, including deferred tax, amounted to RMB 425,743,000 in 2022, up from RMB 213,062,000 in 2021, an increase of 99.9%[29]. - The company recorded revenue of approximately RMB 11,334,300,000, an increase of about 16.8% year-on-year[43]. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was approximately RMB 2,640,800,000, up 40.2% year-on-year[43]. Dividends - The company proposed a final dividend of RMB 14.0 per share, a 75.0% increase from RMB 8.0 in 2021, and a special dividend of RMB 6.0, up 200.0% from RMB 2.0[2]. - The company declared a final dividend of RMB 0.14 per share for 2022, compared to RMB 0.08 per share in 2021, indicating a 75% increase[32]. - The company proposed a final dividend of RMB 14 per share and a special dividend of RMB 6 per share, totaling RMB 25 per share for the year[43]. Research and Development - Research and development expenditure reached RMB 593,600,000, marking a 27.6% increase year-on-year, with significant progress in diabetes and ophthalmology drug development[5]. - Research and development costs for the year were RMB 593,598 thousand, up from RMB 465,243 thousand in the previous year, indicating an increase of about 27.5%[27]. - The company invested RMB 593,600,000 in drug research and development, with R&D expenses increasing by 27.6% year-on-year[46]. - A total of 29 new products are under development, including 15 first-class new drug projects, focusing on endocrine, autoimmune, and ophthalmology fields[46]. - The company received clinical trial approval for the insulin injection and several other new drugs, enhancing its product portfolio in diabetes treatment and ophthalmology[46]. Market Performance - The company’s insulin product sales maintained steady growth following the implementation of the sixth batch of national drug centralized procurement[6]. - The animal health business experienced rapid growth, supported by the implementation of new GMP standards, enhancing market opportunities[7]. - The group’s revenue from the Chinese market (including Hong Kong) was RMB 8,962,740 thousand in 2022, accounting for approximately 79% of total revenue[25]. - The company achieved overseas export sales revenue of RMB 2,371,500,000, a year-on-year increase of 13.1%, accounting for 20.9% of total revenue[44]. - Sales revenue from formulation products was approximately RMB 4,560,300,000, up 13.0% year-on-year[45]. - Antibiotic products, including veterinary formulations, recorded sales revenue of RMB 3,063,000,000, a year-on-year increase of 32.9%[45]. Assets and Liabilities - Non-current assets as of December 31, 2022, totaled RMB 6,464,679, an increase from RMB 6,344,787 in 2021[13]. - Current assets increased to RMB 12,514,946 from RMB 9,986,332 in the previous year, driven by higher inventory and trade receivables[13]. - Current liabilities rose to RMB 7,033,027, compared to RMB 6,535,246 in 2021, reflecting increased trade payables[13]. - The total equity attributable to owners of the company was RMB 10,608,086, up from RMB 9,340,492 in the previous year, indicating a strong capital position[15]. - The company’s total assets reached approximately RMB 18,979,600,000, up from RMB 16,331,100,000 in the previous year, while total liabilities increased to RMB 8,370,200,000 from RMB 6,991,200,000[50]. - The company held interest-bearing borrowings of approximately RMB 2,455,100,000, an increase from RMB 1,831,100,000 in the previous year, with all borrowings due within five years[49]. - The current ratio improved to approximately 1.78 from 1.53 in the previous year, indicating better short-term financial health[50]. Corporate Governance - The company has adopted and complied with the corporate governance code as per the listing rules, with some deviations noted[56]. - The company did not have a CEO as of December 31, 2022, and plans to appoint one in due course[57]. - All directors confirmed compliance with the securities trading code during the covered year[58]. - The audit committee reviewed the consolidated financial statements for the year ending December 31, 2022[59]. Employee and Shareholder Actions - The company employed approximately 13,600 staff as of December 31, 2022, an increase from 13,000 in the previous year[52]. - The company repurchased a total of 12,464,000 shares at a total cost of approximately HKD 51,534,000, all of which were subsequently canceled[54]. - The company purchased a total of 3,324,000 shares in January at an average price of HKD 4.60, with a total cost of HKD 14,786,000[55]. - In March, the company bought 3,068,000 shares at an average price of HKD 4.10, totaling HKD 12,310,000[55]. - In April, the company acquired 5,524,000 shares at an average price of HKD 4.10, with a total expenditure of HKD 22,684,000[55]. - The company made a minor purchase of 4,000 shares in September at HKD 3.20, costing HKD 13,000[55]. - In October, the company purchased 544,000 shares at an average price of HKD 3.20, totaling HKD 1,741,000[55].
联邦制药(03933) - 2022 - 年度业绩